Lentiviral gene transfer vectors and their medicinal applications
The present invention relates to the design of gene transfer vectors and especially provides lentiviral gene transfer vectors suitable for either a unique administration or, for iterative administration in a host, and to their medicinal application (such as vaccination against Immunodeficiency Virus, especially suitable in human hosts). Gene transfer vectors are either integrative or non-integrative (NI) vectors, dependently upon the purpose of their use. The invention relates to the use of gene transfer vectors for unique or for multiple in vivo administration into a host in need thereof. The field of application of the present application concerns in particular animal treatment or treatment of human being (e.g. prophylactic or therapeutic or symptomatic or curative treatment), gene therapy or vaccination in vivo. These vectors may be used to elicit an immune response to prevent or to treat a pathogenic state, including virus infections (for example treatment or prevention against Immunodeficiency Virus and especially against AIDS), parasite and bacterial infections or cancers, and preferably to elicit a protective, long-lasting immune response.
1. A combination of compounds for sequential administration to a mammalian host comprising:
(i) lentiviral vector particles, pseudotyped with a first vesicular stomatitis virus G protein, for a first administration; and
(ii) lentiviral vector particles, pseudotyped with a different, second vesicular stomatitis virus G protein, for a second administration;
wherein neither of the vesicular stomatitis virus G proteins is of the Chadipura strain or Piry strain, and
wherein the first the vesicular stomatitis virus G protein does not sero-neutralize the second vesicular stomatitis virus G protein.
2. The combination of compounds of claim 1 , wherein the first vesicular stomatitis virus G protein is of the Indiana strain.
3. The combination of compounds of claim 2 , wherein the second vesicular stomatitis virus G protein is of the New Jersey strain.
4. The combination of compounds of claim 2 , wherein the second vesicular stomatitis virus G protein is of the SVCV strain.
5. The combination of compounds of claim 2 , wherein the second vesicular stomatitis virus G protein is of the Isfahan strain.
6. The combination of compounds of claim 2 , wherein the second vesicular stomatitis virus G protein is of the Cocal strain.
7. The combination of compounds of claim 1 , wherein the first vesicular stomatitis virus G protein is of the New Jersey strain.
8. The combination of compounds of claim 7 , wherein the second vesicular stomatitis virus G protein is of the Indiana strain.
9. The combination of compounds of claim 7 , wherein the second vesicular stomatitis virus G protein is of the SVCV strain.
10. The combination of compounds of claim 7 , wherein the second vesicular stomatitis virus G protein is of the Isfahan strain.
11. The combination of compounds of claim 7 , wherein the second vesicular stomatitis virus G protein is of the Cocal strain.
12. The combination of compounds of claim 1 , wherein the first vesicular stomatitis virus G protein is of the Isfahan strain.
13. The combination of compounds of claim 12 , wherein the second vesicular stomatitis virus G protein is of the Indiana strain.
14. The combination of compounds of claim 12 , wherein the second vesicular stomatitis virus G protein is of the SVCV strain.
15. The combination of compounds of claim 12 , wherein the second vesicular stomatitis virus G protein is of the New Jersey strain.
16. The combination of compounds of claim 12 , wherein the second vesicular stomatitis virus G protein is of the Cocal strain.
17. The combination of compounds of claim 1 , wherein the first vesicular stomatitis virus G protein is of the SVCV strain.
18. The combination of compounds of claim 17 , wherein the second vesicular stomatitis virus G protein is of the Indiana strain.
19. The combination of compounds of claim 17 , wherein the second vesicular stomatitis virus G protein is of the Isfahan strain.
20. The combination of compounds of claim 17 , wherein the second vesicular stomatitis virus G protein is of the New Jersey strain.
21. The combination of compounds of claim 17 , wherein the second vesicular stomatitis virus G protein is of the Cocal strain.
22. The combination of compounds of claim 1 , wherein the first vesicular stomatitis virus G protein is of the Cocal strain.
23. The combination of compounds of claim 22 , wherein the second vesicular stomatitis virus G protein is of the Isfahan strain.
24. The combination of compounds of claim 22 , wherein the second vesicular stomatitis virus G protein is of the New Jersey strain.
25. The combination of compounds of claim 1 , wherein the lentiviral vector particles for the first or second administration comprise a nucleic acid that encodes at least one human immunodeficiency virus Gag antigen.
26. The combination of compounds of claim 25 , wherein the Gag antigen is a GagΔmyr protein devoid of myristylation.
27. The combination of compounds of claim 1 , wherein one of the vesicular stomatitis virus G proteins comprises the cytoplasmic tail of the vesicular stomatitis virus G protein of the Indiana strain.
28. The combination of compounds of claim 1 , wherein one of the vesicular stomatitis virus G proteins comprises the transmembrane domain of the vesicular stomatitis virus G protein of the Indiana strain.
29. The combination of compounds of claim 1 , wherein one of the vesicular stomatitis virus G proteins comprises the transmembrane and cytoplasmic domain of the vesicular stomatitis virus G protein of the Indiana strain and the ectodomain of the vesicular stomatitis virus G protein of the New Jersey strain.
30. The combination of compounds of claim 1 , wherein the lentiviral vector particles for the first or second administration comprise a nucleic acid comprising a functional lentiviral DNA flap.
31. The combination of compounds of claim 30 , wherein the functional lentiviral DNA flap is an HIV-1 DNA flap.
32. The combination of compounds of claim 1 , wherein the lentiviral vector particles for the first or second administration comprise a nucleic acid comprising a β2 microglobulin promoter.
33. The combination of compounds of claim 1 , wherein the lentiviral vector particles for the first and second administration comprise a nucleic acid comprising a β2 microglobulin promoter.
34. The combination of compounds of claim 1 , wherein the lentiviral vector particles for the first or second administration comprise a nucleic acid comprising an LTR devoid of the enhancer of the U3 region.
35. The combination of compounds of claim 1 , wherein the lentiviral vector particles for the first or second administration comprise a nucleic acid that encodes at least one human immunodeficiency virus Nef, Tat, Rev, or Pol antigen.
36. The combination of compounds of claim 1 , wherein the lentiviral vector particles for the first or second administration are HIV vector particles.
37. The combination of compounds of claim 1 , wherein the lentiviral vector particles for the first and second administration are HIV vector particles.
38. A method for priming and subsequently boosting an immune response in a mammalian host comprising sequentially administering the combination of compounds of claim 1 , wherein the first administration and second administration are administered at different times to a mammalian host.
39. A method for inducing an immune response in a human comprising administering the combination of compounds of claim 1 to a human.
40. The method of claim 39 , wherein the human is infected with a human immunodeficiency virus.